[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200000398A1 - Химические соединения - Google Patents

Химические соединения

Info

Publication number
EA200000398A1
EA200000398A1 EA200000398A EA200000398A EA200000398A1 EA 200000398 A1 EA200000398 A1 EA 200000398A1 EA 200000398 A EA200000398 A EA 200000398A EA 200000398 A EA200000398 A EA 200000398A EA 200000398 A1 EA200000398 A1 EA 200000398A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
sor
cor
halogen
salts
Prior art date
Application number
EA200000398A
Other languages
English (en)
Other versions
EA003087B1 (ru
Inventor
Колин Дейвид Элдред
Эндрю Майкл Кеннет Пеннелл
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA200000398A1 publication Critical patent/EA200000398A1/ru
Publication of EA003087B1 publication Critical patent/EA003087B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Соединение формулы (I), где Rпредставляет собой Cалкил, галоген или водород; Rпредставляет собой алкильную группу с прямой или разветвленной цепью, состоящую из 1-6 атомов углерода; при условии, что когда Rпредставляет собой Cалкил, Rявляется Cалкилом, Rне может представлять собой фенил, возможно замещенный одним или более чем одним заместителем, выбранным из галогена, Cалкила, трифторметила, нитро, циано, -COR, -CONRR, -COR, -SOR, -SOR, -SOH, -SONRR, -OR, -NHSOR, -NHCORи -NRR; и его соли и сольваты, в частности его физиологически приемлемые сольваты и соли. Эти соединения являются агонистами к аденозиновому A1-рецептору.Отчет о международном поиске был опубликован 1999.08.19.
EA200000398A 1997-11-08 1998-11-06 Производные аденозина EA003087B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723590.7A GB9723590D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007023 WO1999024451A2 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists

Publications (2)

Publication Number Publication Date
EA200000398A1 true EA200000398A1 (ru) 2000-12-25
EA003087B1 EA003087B1 (ru) 2002-12-26

Family

ID=10821761

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000398A EA003087B1 (ru) 1997-11-08 1998-11-06 Производные аденозина

Country Status (27)

Country Link
US (2) US6544960B1 (ru)
EP (1) EP1030856B1 (ru)
JP (1) JP2001522859A (ru)
KR (1) KR20010031878A (ru)
CN (1) CN1217952C (ru)
AP (1) AP2000001804A0 (ru)
AT (1) ATE273989T1 (ru)
AU (1) AU763414B2 (ru)
BR (1) BR9813989A (ru)
CA (1) CA2309202C (ru)
DE (1) DE69825779T2 (ru)
EA (1) EA003087B1 (ru)
EE (1) EE04499B1 (ru)
ES (1) ES2222619T3 (ru)
GB (1) GB9723590D0 (ru)
HR (1) HRP20000277A2 (ru)
HU (1) HUP0004102A3 (ru)
ID (1) ID24758A (ru)
IL (2) IL135966A0 (ru)
IS (1) IS5479A (ru)
NO (1) NO20002359L (ru)
NZ (1) NZ504336A (ru)
PL (1) PL340873A1 (ru)
SK (1) SK6702000A3 (ru)
TR (1) TR200001937T2 (ru)
WO (1) WO1999024451A2 (ru)
YU (1) YU26800A (ru)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6576620B2 (en) * 1999-12-03 2003-06-10 Cv Therapeutics, Inc. Method of identifying partial adenosine A1 receptor agonists
GB9930085D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
GB0221694D0 (en) * 2002-09-18 2002-10-30 Glaxo Group Ltd Compounds
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
AU2004209986C1 (en) 2003-02-03 2009-08-13 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
ES2574918T3 (es) * 2003-06-02 2016-06-23 Isis Innovation Limited Tratamiento de la fatiga muscular
US20060280721A1 (en) 2003-06-03 2006-12-14 The Gov Of Usa Represented By Secretary Of Dpt Of Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives
FR2862873A1 (fr) * 2003-12-01 2005-06-03 Pf Medicament Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006303452B2 (en) 2005-10-21 2011-06-09 Novartis Ag Human antibodies against IL13 and therapeutic uses
US7732424B2 (en) * 2005-11-30 2010-06-08 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US7893085B2 (en) 2006-08-21 2011-02-22 Genentech, Inc Aza-benzothiophenyl compounds and methods of use
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
US9211275B2 (en) 2008-01-04 2015-12-15 Isis Innovation Ltd. Ketone bodies and ketone body esters as blood lipid lowering agents
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
CN101602786B (zh) * 2008-06-10 2014-04-30 中国医学科学院药物研究所 N6-取代腺苷衍生物、其制法以及药物组合物与用途
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
CN101857622B (zh) * 2009-04-07 2014-12-03 中国医学科学院药物研究所 一种腺苷衍生物及其制备方法和应用
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
KR101721280B1 (ko) 2009-08-17 2017-03-29 인텔리카인, 엘엘씨 헤테로사이클릭 화합물 및 이의 용도
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
CN104382924B (zh) * 2009-12-10 2017-12-22 中国医学科学院药物研究所 N6‑取代腺苷衍生物和n6‑取代腺嘌呤衍生物及其用途
EP2511283A4 (en) * 2009-12-10 2013-07-03 Inst Materia Medica Cams N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND THEIR USE
SI2523669T1 (sl) 2010-01-11 2017-05-31 Inotek Pharmaceuticals Corporation Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
MX2012010724A (es) 2010-03-26 2012-11-12 Inotek Pharmaceuticals Corp Metodo para reducir la presion intraocular en seres humanos empleando n6-ciclopentiladenosina (cpa), derivados de cpa o profarmacos de los mismos.
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
SMT201700377T1 (it) 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
ES2752030T3 (es) 2012-11-05 2020-04-02 Us Health Cuerpos cetónicos para proteger los tejidos del daño por radiación ionizante
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
WO2014140308A1 (en) 2013-03-14 2014-09-18 Isis Innovation Ltd Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
WO2014152723A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制劑的組合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4868160A (en) * 1985-11-06 1989-09-19 Warner-Lambert Company Method of treating psychosis using N6 -substituted -5'-oxidized adenosine analogs
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
US5652366A (en) * 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
HK1002031A1 (en) * 1990-09-25 1998-07-24 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
DK62592D0 (ru) * 1992-05-14 1992-05-14 Novo Nordisk As
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
JPH07118156A (ja) * 1993-10-26 1995-05-09 Nippon Zoki Pharmaceut Co Ltd アデノシンデアミナーゼ阻害剤
JPH08269083A (ja) * 1995-04-03 1996-10-15 Banyu Pharmaceut Co Ltd Ｎ６−置換アデノシン誘導体
AU2022497A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
UA51716C2 (ru) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. СОЕДИНЕНИЯ, ИМЕЮЩИЕ ГИПОТЕНЗИВНОЕ, КАРДИОПРОТЕКТОРНОЕ, АНТИ-ИШЕМИЧЕСКОЕ И АНТИЛИПОЛИТИЧЕСКОЕ СВОЙСТВА, фармацевтическая композиция и способЫ лечения
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CA2309202A1 (en) 1999-05-20
EE200000283A (et) 2001-08-15
EE04499B1 (et) 2005-06-15
IL135966A0 (en) 2001-05-20
US6544960B1 (en) 2003-04-08
ID24758A (id) 2000-08-03
CA2309202C (en) 2008-06-17
US6740644B2 (en) 2004-05-25
SK6702000A3 (en) 2001-01-18
AP2000001804A0 (en) 2000-06-30
DE69825779D1 (de) 2004-09-23
YU26800A (sh) 2002-12-10
ATE273989T1 (de) 2004-09-15
HUP0004102A3 (en) 2002-09-30
EA003087B1 (ru) 2002-12-26
TR200001937T2 (tr) 2000-11-21
WO1999024451A2 (en) 1999-05-20
HRP20000277A2 (en) 2000-10-31
GB9723590D0 (en) 1998-01-07
JP2001522859A (ja) 2001-11-20
NZ504336A (en) 2002-11-26
NO20002359L (no) 2000-07-05
EP1030856A2 (en) 2000-08-30
BR9813989A (pt) 2000-09-26
HUP0004102A2 (hu) 2001-04-28
AU763414B2 (en) 2003-07-24
NO20002359D0 (no) 2000-05-05
DE69825779T2 (de) 2005-08-25
WO1999024451A3 (en) 1999-08-19
KR20010031878A (ko) 2001-04-16
IL135966A (en) 2006-06-11
AU1666599A (en) 1999-05-31
CN1217952C (zh) 2005-09-07
IS5479A (is) 2000-05-03
US20030158146A1 (en) 2003-08-21
EP1030856B1 (en) 2004-08-18
PL340873A1 (en) 2001-03-12
CN1285844A (zh) 2001-02-28
ES2222619T3 (es) 2005-02-01

Similar Documents

Publication Publication Date Title
EA200000398A1 (ru) Химические соединения
EA200000392A1 (ru) Химические соединения
EA200000393A1 (ru) Химические соединения
DK0931788T3 (da) Metalloproteasehæmmere
ES2188016T3 (es) Derivaqdo de benzamidoxima, productos intermedios y procedimiento para su obtencion y su empleo como fungicidas.
DE60004637D1 (de) N2-phenylamidine derivate
ES2155219T3 (es) Compuestos nucleotidos de fosfonato.
HUP9903836A2 (hu) Új eljárás Cox-2 inhibítor hatású fenil-szubsztituált 2(5H)-furanonok előállítására
EA199800987A1 (ru) Бензоксазиноновые антагонисты рецептора допамина d4
DK0759027T3 (da) Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
ES8504130A1 (es) Un metodo para preparar derivados de 4-hidroxi-2-quinolona
ES507996A0 (es) Un procedimiento para la preparacion de un compuesto de pirimidoquinazolina.
ES2039221T3 (es) Procedimiento para producir derivados de piridazinona.
DE3770419D1 (de) Substituierte 2-phenylimino-oxazolidin-derivate mit herbizider wirkung.
ES465225A1 (es) Procedimiento para la preparacion de n-cicloalcohilmetil-2- fenilamino-imidazolinas-(2).
NO995289L (no) Benzimidazol-derivater
EA200000560A1 (ru) Бензилиденпиразолоны, способ их получения и применения
NZ228091A (en) Substituted hydrazones and fungicidal compositions
EA200001036A1 (ru) Способы ингибирования mrp1
ES476632A1 (es) Procedimiento para preparar derivados de anilida con susti--tucion heterociclica.
ES518521A0 (es) Procedimiento para la obtencion de un medio antimicotico.
ES2188041T3 (es) Mezclas de fungicidas a base de piridincarboxamidas.
EA199900684A1 (ru) Производные иминоазаантрациклинона для лечения амилоидоза
EA199800083A1 (ru) Производные 1,3-оксазин-4-она в качестве гербицидов
KR880011087A (ko) 제초제

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU